sur FSD Pharma Inc.
FSD Pharma launches a clinical trial to test the effectiveness of unbuzzd™
Toronto-based biopharmaceutical company FSD Pharma has announced a collaboration through its Australian subsidiary with Ingenu CRO Pty Ltd. This agreement, signed on February 19, 2024, aims to launch a clinical trial entitled “METAL-1 TRIAL”. The objective is to evaluate the safety and effectiveness of unbuzzd™, a dietary supplement intended to accelerate sobriety after alcohol consumption.
The unbuzzd™ product is an enriched liquid formula that may improve cognition and speed up alcohol metabolism, helping to regain sobriety faster. Behind unbuzzd™ is Celly Nutrition Corp., led by leading beverage and marketing leaders.
In parallel, FSD Pharma is working to develop a medical product aimed at accelerating alcohol metabolism for use in medical centers and by frontline workers. This trial marks a crucial milestone in the development of unbuzzd™, highlighted by the company's commitment to R&D, led by Zeeshan Saeed, co-founder and CEO.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de FSD Pharma Inc.